However, recent studies have shown that NSCLC patients with KRAS mutations have different degrees of sensitivity to ICIs treatment, and KRAS mutations are significant in enhancing PD-L1 expression, promoting T cell infiltration, and enhancing tumor immunogenicity52,54,55. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.